These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 34373119)

  • 1. Implementing vaccination policies based upon scientific evidence in Japan.
    Yoshikawa T
    Vaccine; 2021 Sep; 39(38):5447-5450. PubMed ID: 34373119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap.
    Saitoh A; Okabe N
    Vaccine; 2021 May; 39(22):3018-3024. PubMed ID: 33931250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects.
    Buchy P; Chen J; Zhang XH; Benninghoff B; Lee C; Bibera GL
    Expert Rev Vaccines; 2021 Dec; 20(12):1499-1514. PubMed ID: 33275065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotavirus vaccination in Japan: Efficacy and safety of vaccines, changes in genotype, and surveillance efforts.
    Tsugawa T; Akane Y; Honjo S; Kondo K; Kawasaki Y
    J Infect Chemother; 2021 Jul; 27(7):940-948. PubMed ID: 33867267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Technical guidelines for seasonal influenza vaccination in China (2020-2021)].
    National Immunization Advisory Committee Technical Working Group
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1035-1059. PubMed ID: 33131228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation.
    Yousaf AR; Cortese MM; Taylor AW; Broder KR; Oster ME; Wong JM; Guh AY; McCormick DW; Kamidani S; Schlaudecker EP; Edwards KM; Creech CB; Staat MA; Belay ED; Marquez P; Su JR; Salzman MB; Thompson D; Campbell AP;
    Lancet Child Adolesc Health; 2022 May; 6(5):303-312. PubMed ID: 35216660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public preferences and willingness to accept a hypothetical vaccine to prevent a pandemic in Japan: a conjoint analysis.
    Igarashi A; Nakano Y; Yoneyama-Hirozane M
    Expert Rev Vaccines; 2022 Feb; 21(2):241-248. PubMed ID: 35073824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress and challenges for the Japanese immunization program: Beyond the "vaccine gap".
    Saitoh A; Okabe N
    Vaccine; 2018 Jul; 36(30):4582-4588. PubMed ID: 29929825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-SARS-CoV-2 vaccination strategy for pregnant women in Japan.
    Hayakawa S; Komine-Aizawa S; Takada K; Kimura T; Yamada H
    J Obstet Gynaecol Res; 2021 Jun; 47(6):1958-1964. PubMed ID: 33754418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
    Javanbakht M; Moradi-Lakeh M; Yaghoubi M; Esteghamati A; Mansour Ghanaie R; Mahmoudi S; Shamshiri AR; Zahraei SM; Baxter L; Shakerian S; Chaudhri I; Fleming JA; Munier A; Baradaran HR
    Vaccine; 2015 May; 33 Suppl 1():A192-200. PubMed ID: 25919160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.